INVICTUS is a comprehensive evaluation of RVHD, AF and stroke. The study includes three components, A registry of RVHD, a randomized clinical trial of rivaroxaban versus Vitamin K antagonist therapy (VKA) to establish the non-inferiority and potential superiority of rivaroxaban compared to VKA and a superiority trial to compare rivaroxaban to aspirin in patients who are unsuitable for VKA therapy or who do not have AF/flutter but who do have other risk factors.
INVICTUS study will establish the efficacy and safety of rivaroxaban in a broad cross section of patients at substantial risk of stroke and death. Currently this program is being carried out in 27 countries with 171 centres. In India, the study has been activated in 09 tertiary care hospitals (AIIMS, GB Pant and RML in Delhi, SGPGI and KGMC in Lucknow, Sri Jayadev in Bangalore, PGIMER in Chandigarh, SMS in Jaipur and JIPMER in Pondicherry). CDSA has extended pre-study activities support and accomplished activation of all clinical sites in India.
- Ms. Shubhra Bansal
- Mr. Tarun Puri
- Ms. Jinisha Shukla